Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
Hematol., Transfus. Cell Ther. (Impr.)
;
42(3): 195-199, July-Sept. 2020.
Article
in English
| LILACS
| ID: biblio-1134039
ABSTRACT
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
SARS-CoV-2
/
COVID-19
/
Myeloproliferative Disorders
Type of study:
Practice guideline
Limits:
Humans
Language:
English
Journal:
Hematol., Transfus. Cell Ther. (Impr.)
Journal subject:
Hematologia
/
TransfusÆo de Sangue
Year:
2020
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital Israelita Albert Einstein/BR
/
Universidade Estadual de Campinas/BR
/
Universidade Federal de Goiás - UFG/BR
Similar
MEDLINE
...
LILACS
LIS